Published in Hepatology on September 01, 2010
Spironolactone Therapy In Young Women With NASH | NCT03576755
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology (2011) 3.00
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology (2012) 2.93
Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2013) 2.50
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (2012) 2.10
Ethnicity and nonalcoholic fatty liver disease. Hepatology (2012) 1.98
NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol (2013) 1.90
Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol (2011) 1.85
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver (2012) 1.70
Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res (2011) 1.42
Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr (2013) 1.35
Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol (2014) 1.29
Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care (2012) 1.19
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology (2015) 1.18
The de ritis ratio: the test of time. Clin Biochem Rev (2013) 1.14
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2013) 1.12
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology (2013) 1.10
Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol (2012) 1.07
Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis (2012) 1.06
NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol (2015) 1.05
Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy. J Gastroenterol (2011) 1.00
Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther (2015) 1.00
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology (2015) 1.00
Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int (2013) 0.97
Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y) (2013) 0.94
Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology (2012) 0.93
Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol (2013) 0.92
Drosophila tools and assays for the study of human diseases. Dis Model Mech (2016) 0.91
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr (2012) 0.89
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2014) 0.88
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care (2015) 0.88
Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterol Res Pract (2013) 0.88
The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci (2016) 0.88
Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol (2013) 0.87
Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y) (2012) 0.87
Association between platelet count as a noninvasive marker and ultrasonographic grading in patients with nonalcoholic Fatty liver disease. Hepat Mon (2015) 0.87
Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging (2014) 0.86
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab (2011) 0.86
Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol (2013) 0.85
Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2014) 0.84
Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic Fatty liver disease. Dig Dis Sci (2015) 0.83
Vitamin D Deficiency Is Associated With Increased Risk of Non-alcoholic Steatohepatitis in Adults With Non-alcoholic Fatty Liver Disease: Possible Role for MAPK and NF-κB? Am J Gastroenterol (2016) 0.83
Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol (2013) 0.82
Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol (2015) 0.82
Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. PLoS One (2013) 0.82
A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology (2016) 0.82
Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS One (2013) 0.82
Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. J Inflamm Res (2012) 0.82
Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood) (2015) 0.81
Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver. Exp Ther Med (2014) 0.81
Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol (2014) 0.80
The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol (2014) 0.80
Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance. Clin Liver Dis (2016) 0.79
Amount of hepatic fat predicts cardiovascular risk independent of insulin resistance among Hispanic-American adolescents. Lipids Health Dis (2015) 0.79
Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? PLoS One (2014) 0.79
Intravoxel Incoherent Motion Diffusion Weighted MR Imaging at 3.0 T: Assessment of Steatohepatitis and Fibrosis Compared with Liver Biopsy in Type 2 Diabetic Patients. PLoS One (2015) 0.78
Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res (Hoboken) (2014) 0.78
Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Sci Rep (2016) 0.78
Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol (2016) 0.77
Noninvasive markers for the diagnosis of nonalcoholic Fatty liver disease. Endocrinol Metab (Seoul) (2013) 0.77
A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid. Ups J Med Sci (2010) 0.77
Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology (2016) 0.77
NAFLD: The role of exercise in treating NAFLD. Nat Rev Gastroenterol Hepatol (2012) 0.77
Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. Br J Radiol (2016) 0.77
Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol (2015) 0.76
Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int (2014) 0.76
A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit. PLoS One (2014) 0.76
Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology (2016) 0.76
Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin. Clin Gastroenterol Hepatol (2013) 0.76
Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin (2014) 0.76
Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol (2016) 0.76
Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats. Sci Rep (2017) 0.75
Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol (2016) 0.75
Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One (2017) 0.75
Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients. PLoS One (2015) 0.75
Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology (2011) 0.75
Association between sonographic diagnosis of fatty liver with histopathologic abnormalities and liver biopsy findings in middle age patient with non-alcoholic fatty liver disease. Adv Biomed Res (2016) 0.75
The Wide and Complex Field of NAFLD Biomarker Research: Trends. ISRN Hepatol (2014) 0.75
Association of the Nonalcoholic Hepatic Steatosis and Its Degrees With the Values of Liver Enzymes and Homeostasis Model Assessment-Insulin Resistance Index. Gastroenterology Res (2015) 0.75
Sex differences in the association of HIV infection with hepatic steatosis. AIDS (2016) 0.75
Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis (2015) 0.75
Comparison of liver enzymes level and sonographic findings value with liver biopsy findings in nonalcoholic fatty liver disease patients. Adv Biomed Res (2016) 0.75
Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis. Dig Dis Sci (2017) 0.75
Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. Dig Dis Sci (2017) 0.75
Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol (2017) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med (2002) 10.78
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med (2008) 5.27
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology (2001) 5.07
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol (2006) 4.52
Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ (2004) 4.22
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut (2008) 3.88
Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology (2009) 3.67
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol (2006) 3.62
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology (2008) 2.33
Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem (2007) 2.29
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol (1998) 2.13
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology (2006) 2.04
Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis (2008) 2.04
A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology (2008) 1.93
Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology (2008) 1.92
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol (2007) 1.90
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol (2004) 1.76
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials (2009) 1.48
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.47
Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci (2003) 1.37
Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels. Arch Intern Med (2008) 1.25
Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int (2006) 1.21
Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care (2005) 1.14
Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int (2007) 1.02
'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol (2004) 0.94
Nonalcoholic fatty liver disease liver fat score and fat equation to predict and quantitate hepatic steatosis: promising but not prime time! Gastroenterology (2009) 0.85
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature (2008) 10.84
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med (2000) 8.32
The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol (2003) 8.23
Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med (2011) 7.81
Prevalence of fatty liver in children and adolescents. Pediatrics (2006) 7.00
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet (2014) 6.84
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med (2008) 5.27
Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15
Alcoholic liver disease. Hepatology (2010) 5.04
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med (2013) 4.25
Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology (2005) 4.21
Nonalcoholic fatty liver disease. Gastroenterology (2002) 4.15
Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging (2008) 4.13
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (2003) 4.03
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology (2014) 4.01
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med (2015) 3.79
Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology (2010) 3.73
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis (2008) 3.69
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring) (2011) 3.62
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med (2012) 3.51
Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA (2003) 3.51
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol (2010) 3.36
Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology (2005) 3.35
SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell (2011) 3.33
Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol (2008) 3.33
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Heritability of nonalcoholic fatty liver disease. Gastroenterology (2009) 3.17
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum (2007) 3.12
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr (2006) 3.03
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol (2007) 2.98
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97